RxDoctor Payments Data

Bryan Gayne, DO

Family Medicine · St Petersburg, FLNPI 1023541992

Payments from drug & device makers

$947in general payments, 2019–2025

Across 43 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$150
  • GSK$133
  • Exact Sciences$110
  • Inspire Medical Systems, Inc.$102
  • AbbVie$66
  • Dexcom, Inc.$48
  • plus $338 from 13 others

What the payments were for

  • Food & beverage$947100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$947 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$46,275
Medicare patients
133
Services billed
688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$49,998
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,536
TrulicityDulaglutide13$13,923
JardianceEmpagliflozin12$12,364
XareltoRivaroxaban13$11,146
MyrbetriqMirabegron20$9,477
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,252
SymbicortBudesonide/Formoterol Fumarate17$6,022
Omeprazole97$2,666
Albuterol Sulfate HfaAlbuterol Sulfate61$2,604
Levothyroxine Sodium215$2,137
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen62$2,055
Potassium Chloride26$1,838
Atorvastatin Calcium169$1,493
Gabapentin76$1,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$49,99845 claims
GSKTrelegy Ellipta$133$15,53616 claims
Lilly USA, LLCTrulicity, Humulin N$21$14,38724 claims
Boehringer IngelheimJardiance$30$12,36412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →